Научные статьиM.H.Sayidova, S.U.Pulatova2025
LASER-ASSISTED TREATMENT OF ORAL MUCOSAL DISEASES IN PATIENTS WITH CHRONIC RENAL FAILURE: CLINICAL OUTCOMES AND EVIDENCE-BASED RECOMMENDATIONS
AND EVIDENCE-BASED RECOMMENDATIONS · Sabirov Bobur Kadirbaevich · Khabibova Nazira Nasullaevna
Современные подходы и новые исследования в современной науке · 2026
Аннотация
Oral mucosal diseases are prevalent among patients with chronic kidney disease (CKD) and are often complicated by oxidative stress and immune dysregulation. This study evaluates the clinical outcomes of integrating low-level laser blood irradiation (LLLI) with conventional antiseptic therapy in the management of oral inflammatory conditions in CKD patients. The prospective controlled trial included 100 CKD patients with chronic inflammatory oral lesions, divided into a control group receiving standard antiseptic therapy and a main group additionally treated with LLLI and immunomodulatory antiseptics. Clinical assessments, along with biochemical and immunological parameters, were used to evaluate treatment efficacy. The results demonstrated superior outcomes in the LLLI group, including improved epithelial healing, reduced recurrence, and enhanced biochemical markers, supporting the integration of LLLI into standard care protocols. Keywords: chronic kidney disease, oral mucosal disease, laser therapy, inflammation, immunomodulation, clinical dentistry, antiseptic treatment, cytokines Introduction: Chronic kidney disease (CKD) leads to systemic complications that adversely affect the oral cavity. Oral mucosal inflammation, characterized by erythema, ulceration, and chronic discomfort, is frequently observed in CKD patients. These manifestations are linked to reduced salivary flow, altered electrolyte balance, and impaired immune responses. Traditional treatment approaches rely on antiseptic and symptomatic therapy; however, recurrence and prolonged healing remain clinical challenges. Low-level laser therapy (LLLT), particularly laser blood irradiation, has shown promise in improving microcirculation, stabilizing cellular membranes, and modulating oxidative stress and inflammation. By enhancing endogenous antioxidant defense and promoting cytokine balance, LLLT may serve as a valuable adjunct in treating oral conditions in immunocompromised patients, including those with CKD. 85 CURRENT APPROACHES AND NEW RESEARCH IN MODERN SCIENCES International scientific-online conference This study explores the practical application, clinical efficacy, and systemic impact of combining LLLT with antiseptic therapy for oral mucosal diseases in CKD patients. Materials and Methods: A total of 100 adult CKD patients with diagnosed chronic inflammatory oral mucosal conditions (e.g., gingivitis, stomatitis, ulcerative lesions) were enrolled and randomly assigned to two groups: Control group (n=50): Received standard topical antiseptic treatment and anti-inflammatory agents. Main group (n=50): Received the same treatment plus low-level laser blood irradiation (LLLI) and an immunomodulatory antiseptic. Clinical Inclusion Criteria: Age 30–65 years CKD stages 3–5 (on conservative or dialysis therapy) Non-smoking and non-diabetic status Absence of systemic immunosuppressive therapy Treatment Protocol: LLLI: Intravenous laser irradiation using a 635 nm wavelength, 10 minutes/session, 10 sessions over 2 weeks Antiseptics: Chlorhexidine and lysozyme-based rinses used three times daily for 14 days Clinical Assessment: Mucosal healing, lesion regression, recurrence rate at 30 and 60 days post-treatment Laboratory Measures: Lipid peroxidation (LOOH), catalase activity, cytokines (IL-1β, IL-6, IL-2) Statistical Evaluation: Data were analyzed using STATISTICA 6.0. Student's t-test and Chi-square test were applied. A p-value <0.05 was considered statistically significant. Results: Clinical Findings: Patients in the main group showed faster epithelial healing, with average recovery in 5.7 ± 1.2 days, compared to 9.3 ± 1.8 days in the control group (p<0.001). Pain intensity measured using the Visual Analog Scale (VAS) decreased more rapidly in the main group (from 6.8 to 1.2) versus the control group (from 6.6 to 2.9). At 30 days post-treatment, recurrence of lesions occurred in 18% of control patients versus only 6% in the main group. At 60 days, these figures were 30% and 12%, respectively, indicating sustained benefits of laser therapy. Biochemical Markers: 86 CURRENT APPROACHES AND NEW RESEARCH IN MODERN SCIENCES International scientific-online conference LOOH: Decreased from 2.91 ± 0.11 to 1.48 ± 0.07 in the main group (p<0.001), compared to 2.89 ± 0.12 to 2.05 ± 0.09 in the control group (p<0.05) Catalase: Increased from 9.01 ± 0.65 to 16.23 ± 0.79 in the main group (p<0.01), versus 8.94 ± 0.62 to 12.87 ± 0.84 in the control group (p<0.05) Cytokine Regulation: IL-1β: Reduced from 5.47 ± 0.42 to 3.06 ± 0.21 in the main group (p<0.01), vs. 5.41 ± 0.39 to 4.32 ± 0.27 in controls (p<0.05) IL-6: Reduced from 5.93 ± 0.48 to 2.79 ± 0.26 in the main group (p<0.001), vs. 5.88 ± 0.51 to 4.12 ± 0.35 in controls (p<0.05) IL-2: Increased from 5.57 ± 0.46 to 9.82 ± 0.61 in the main group (p<0.01), vs. 5.62 ± 0.49 to 7.98 ± 0.54 in controls (p<0.05) Discussion: The results clearly support the clinical utility of integrating LLLT into treatment protocols
Доказательный фрагмент
«Oral mucosal diseases are prevalent among patients with chronic kidney disease (CKD) and are often complicated by oxidative stress and immune dysregulation.»
Образец извлечения
Демо-превьюOral mucosal diseases are prevalent among patients with chronic kidney disease (CKD) and are often complicated by oxidative stress and immune dysregulation. Полный текст публикации CiteX не хранит — доступ к первоисточнику открывается по DOI согласно лицензии издателя и выбранному плану.
- Цитирований
- 0
- Просмотров
- 0
- Тип
- Журнал
- Страна
- Узбекистан
- Ключевые слова
- chronic kidney disease, oral mucosal disease, laser therapy, antiseptic treatment, immunomodulation, cytokines, inflammation, clinical dentistry
Смежные источники
Общество и инновацииKhosiyat MAMATKULOVA2024
Академические исследования в современной наукеKhudaiberdiyeva Arafat Israilovna, Ph.D Professor hudayberdiyevaarofat@gmail.com +12026
Научные статьиI.B.Yangiboyev, E.X.Berdanov +22025